%PDF-1.3
%
7 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
12 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2016-08-08T10:53:32-07:00
2016-08-04T06:36:44+05:30
application/pdf
BFM-2016-0125-ver9-Anderson_2P 1..3
uuid:de2d73b0-8ece-47bb-9085-5ab9f3a9f6a7
uuid:984549a0-efc6-4e02-8247-b4cd7cc6d0f3
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
20 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
9.843 0 0 9.843 62.022 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(is)-209.5(on)20.8(ly)-203.9(10)20.8(0)-156.6(m)0(g)-205(d)0(a)19.7(i)0(l)14.8(y)0(.)-206.1(T)0(w)18.8(o)-214.2(st)20.9(ud)20.8(ie)19.6(s)-219.8(w)0(i)19.8(t)0(h)-203.9(t)0(h)20.7(e)-221.1(30)20.8(0)-156.6(m)0(g)19.6(/)0(d)20.7(a)0(y)-205(d)0(o)15.1(s)0(a)19.9(g)0(e)]TJ
0 -1.1174 TD
[(co)19.7(mp)19.6(ar)19.7(ed)-441.1(in)20.7(fa)19.7(nt)-440.1(pl)20.7(as)14.1(m)15(a)-451.5(co)19.7(nc)19.7(en)19.7(tr)15(at)19.6(io)20.7(ns)-439.7(wi)19.8(th)-440.1(th)20.7(os)21(e)-451.5(o)0(f)-434.1(t)0(h)15(e)0(i)19.5(r)]TJ
0 -1.1116 TD
[(mo)19.6(th)20.7(er)-360.4(an)19.7(d)-369.7(f)0(o)20.9(u)0(n)20.8(d)-369.7(th)20.7(at)-360.6(me)18.4(di)20.7(an)-360.5(in)20.7(fa)19.7(nt)-359.4(pl)20.7(as)19.9(ma)-361.7(co)19.7(nc)19.7(en)19.7(tr)20.7(at)19.5(io)15(ns)]TJ
T*
[(we)18.8(re)-262.5(on)20.8(ly)-261.5(2)20.8(6%)-262.4(of)-261.4(th)20.7(e)-273(m)15(at)13.8(er)19.7(na)19.7(l)-271.9(p)0(l)20.7(a)0(s)19.9(m)0(a)-263.8(l)0(e)19.6(v)0(e)19.7(l)0(s)20.9(.)]TJ
7.3823 0 0 6.5614 245.7637 696.6423 Tm
(5)Tj
9.843 0 0 9.843 72 681.3352 Tm
[(Adefovir,)-267.8(entecavir,)-271.7(and)-263.7(telbivudine)-268.4(also)-264.7(have)-265.9(indications)]TJ
-1.0137 -1.1174 TD
[(for)-406.4(treatment)-412.4(of)-405.3(hepatitis)-410(B)-405.3(and)-407.6(emtricitabine)-412.5(is)-405.3(used)-408.6(off-)]TJ
0 -1.1116 TD
[(label.)-420.5(Neither)-414.3(adefovir,)-417.8(entecavir,)-421.4(nor)-418(telbivudine)-418.1(has)-413.2(any)]TJ
T*
[(available)-383.6(information)-377.7(on)-376.6(its)-377.7(use)-378.6(during)-375.3(breastfeeding.)-379.5(Em-)]TJ
0 -1.1174 TD
[(tricitabine)-413.6(has)-413.2(been)-409.9(studied)-412.1(in)-411.3(only)-407.7(ve)-413.2(HIV)]TJ
/F2 1 Tf
18.9091 0 TD
(+)Tj
/F7 1 Tf
.9619 0 TD
[(mothers)-413.2(in)]TJ
-19.871 -1.1116 TD
[(whom)-340.6(about)-340.9(2%)-343.1(of)-342(the)-338.7(relative)-346.7(infant)-342.1(dosage)-342.8(was)-339.2(excreted)]TJ
T*
[(into)-367.5(breastmilk.)-363.8(These)-371.7(drugs)-362.4(should)-363.6(be)-366.2(considered)-371.5(second-)]TJ
0 -1.1174 TD
[(line)-558.8(alternative)-558.7(therapies)-560.6(in)-555.3(nursing)-554.8(mothers)-557.2(because)-559.3(of)]TJ
0 -1.1116 TD
[(the)-332.9(lack)-329.4(of)-330.5(information)-331.6(during)-329.2(breastfeeding.)-333.4(In)-330.5(addition)-332.9(to)]TJ
T*
[(these)-203.6(oral)-201.5(agents,)-202.4(interferon)-203.6(alfa-2b)-205.9(and)-200.3(peginterferon)-208(alfa-2a)]TJ
T*
[(are)-333.9(approved)-333.7(for)-325.8(treating)-334(hepatitis)-335.1(B,)-333.9(but)-326(they)-334(are)-333.9(given)-329.3(by)]TJ
0 -1.1174 TD
[(injection)-531.1(and)-522.8(less)-523.7(prefer)-8.8(red.)-520.5(The)-529.8(amounts)-528.4(of)-520.5(these)-526.1(alfa-)]TJ
0 -1.1116 TD
[(interferons)-273.6(were)-266.8(very)-264.7(low)-269.2(in)-267.3(the)-263.8(breastmilk)-273.9(of)-267.1(three)-267.1(mothers)]TJ
T*
[(studied.)-415.6(Plasma)-418.9(levels)-417.9(in)-411.3(breast-fed)-417.5(infants)-417.8(have)-415.7(not)-412.4(been)]TJ
0 -1.1174 TD
[(measured,)-229.9(but)-228.1(the)-229.2(infant)-232.6(would)-225.4(receive)-237.1(them)-225.8(orally,)-230.3(reducing)]TJ
0 -1.1116 TD
[(the)-281.1(likelihood)-283.4(of)-278.6(their)-283.4(systemic)-282.9(absorption.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 62.022 489.4298 Tm
[(Hepatitis)-336.5(C)]TJ
/F7 1 Tf
9.843 0 0 9.843 72 472.9889 Tm
[(The)-224.5(rst)-228.8(consideration)-231.1(is)-226.8(that)-230.5(hepatitis)-231.4(C)-226.8(i)0(s)-226.8(not)-228.1(transmitted)]TJ
-1.0137 -1.1116 TD
[(through)-226.7(breastmilk)]TJ
7.3823 0 0 6.5614 136.6299 466.4125 Tm
(6,7)Tj
9.843 0 0 9.843 148.0818 462.0471 Tm
[(and)-229.1(breastmilk)-227.8(has)-223.1(even)-231.4(been)-225.6(shown)-225(to)]TJ
-8.7432 -1.1116 TD
[(inactivate)-275.4(hepatitis)-271.7(C)-255.6(v)16.2(ir)26.5(us)-243.9(\(H)25.8(CV)24.7(\).)]TJ
7.3823 0 0 6.5614 199.1055 455.4707 Tm
-.0179 Tc
(8,9)Tj
9.843 0 0 9.843 210.6141 451.1054 Tm
0 Tc
[(A)15.3(l)0(t)20.6(h)16.2(ou)26.6(gh)-244.1(b)16.2(r)0(e)19.7(a)15(st)26.7(fe)19.7(e)15(d)0(i)26.5(n)0(g)]TJ
-15.0962 -1.1174 TD
[(is)-405.3(no)20.8(t)-415.9(c)0(o)25.4(n)0(t)26.5(r)0(a)19.7(i)16.1(nd)26.6(ic)25.3(at)19.5(e)15(d)0(,)-407.7(t)16.1(he)-412.3(C)15.2(e)0(n)25.4(t)0(e)25.3(r)0(s)-410.9(f)16.2(or)-411.1(D)15.3(i)0(s)26.7(e)0(a)24.3(s)0(e)-412.1(C)15.2(on)26.6(tr)26.5(ol)-411.3(a)15(n)0(d)]TJ
0 -1.1116 TD
[(Pr)26.8(ev)25.4(en)19.7(t)16.1(i)0(o)26.5(n)-525.2(re)25.5(co)25.4(mm)24.1(en)25.4(ds)-514.6(t)16.1(h)0(a)25.4(t)-525.4(m)15(o)0(t)26.5(h)0(e)19.7(r)16.2(s)-525(w)0(i)25.6(t)0(h)-509.2(H)0(C)18.9(V)-520.3(in)26.5(fe)19.7(c)15(t)0(i)26.3(o)0(n)]TJ
T*
[(sh)26.8(ou)26.6(ld)-278.8(c)15(o)0(n)26.6(s)0(i)26.7(d)0(e)19.7(r)-283.3(ab)25.4(st)26.7(ai)19.5(n)16.2(i)0(n)26.5(g)-289.1(f)16.2(r)0(o)20.9(m)-284.5(b)16.2(r)0(e)19.7(a)15(st)26.7(fe)19.7(e)15(d)0(i)26.5(n)0(g)-272.9(i)0(f)-273(t)0(h)20.7(e)15(ir)-273(ni)26.5(pp)20.8(l)16.1(e)0(s)]TJ
T*
[(ar)25.5(e)-307.5(c)0(r)25.5(a)0(c)18.5(k)16.2(ed)-297.1(o)16.2(r)-306.3(bl)20.7(e)15(e)0(d)25.4(i)0(n)26.5(g)0(.)]TJ
7.3823 0 0 6.5614 156.359 411.6471 Tm
(7)Tj
9.843 0 0 9.843 163.1055 407.2818 Tm
[(I)16.2(t)-306.5(is)-295.9(no)26.6(t)-312.3(c)15(le)25.3(ar)-297.1(w)15.3(h)0(e)19.7(t)16.1(he)25.4(r)-306.3(t)0(h)20.7(i)16.1(s)-306.2(w)0(a)24.6(r)0(n)20.9(i)16.1(ng)]TJ
-10.2696 -1.1174 TD
[(ap)25.4(pl)26.5(ie)25.3(s)-173.7(e)0(q)19.7(u)16.2(al)25.3(ly)-163.6(t)16.1(o)-173.9(mo)25.4(th)26.5(er)25.5(s)-173.7(w)0(h)25.7(o)-173.9(ar)25.5(e)-175(r)0(e)25.5(c)0(e)18.5(i)16.1(vi)26.5(ng)-163.5(d)16.2(r)0(u)26.6(g)-173.9(tr)20.7(e)15(a)0(t)25.3(m)0(e)24.2(n)0(t)-163.6(f)16.2(or)]TJ
0 -1.1116 TD
[(he)25.4(pa)25.4(ti)26.3(ti)20.6(s)-225.5(C)15.2(.)-228.1(C)15.2(ur)26.6(re)19.7(n)16.2(t)-225.9(re)25.5(co)25.4(mm)24.1(en)25.4(da)25.4(ti)20.6(o)16.2(n)0(s)-215.1(f)16.2(ur)20.9(t)16.1(h)0(e)25.4(r)-225.7(st)20.9(a)15(t)0(e)-216.6(t)16.1(ha)25.4(t)-225.9(i)0(n)26.5(f)0(a)19.7(n)16.2(ts)]TJ
T*
[(bo)26.6(rn)-215.3(t)16.1(o)-225.7(mo)25.4(th)26.5(er)19.7(s)-225.5(w)15.3(it)26.3(h)-225.7(H)0(C)24.7(V)-226.6(in)26.5(fe)25.5(ct)25.3(io)20.7(n)-225.7(s)16.4(ho)26.6(ul)20.7(d)-220(b)0(e)-216.5(t)16.1(es)19.9(t)16.1(e)0(d)-216.5(f)16.2(or)-215.3(H)15.3(C)0(V)]TJ
0 -1.1174 TD
[(in)26.5(fe)25.5(ct)19.5(i)16.1(o)0(n)26.6(.)-239.6(Be)24.4(ca)24.3(us)26.8(e)-244.2(m)15(at)25.3(er)25.5(na)19.7(l)-237.4(a)15(nt)20.7(i)16.1(b)0(o)26.6(d)0(y)-226.8(i)0(s)-226.8(p)0(r)26.6(e)0(s)19.9(e)15(nt)-227(fo)26.6(r)-243(t)16.1(he)-228(r)26.8(st)-226.8(18)]TJ
0 -1.1116 TD
[(m)15(o)0(n)20.8(t)16.1(hs)-301.5(of)-307.4(l)16.1(i)0(f)26.5(e)-319(a)15(n)0(d)-307.5(b)16.2(ef)25.5(or)26.6(e)-319(t)16.1(he)-308.6(i)16.1(n)0(f)26.6(a)0(n)25.4(t)-318(m)15(o)0(u)20.8(n)16.2(ts)-301.6(an)-302.9(im)25.2(mu)25.4(no)26.6(lo)20.7(g)16.2(i)0(c)]TJ
T*
[(re)25.5(sp)26.8(on)20.8(s)16.4(e)0(,)-259.1(n)16.2(uc)25.4(le)25.3(ic)-256.9(ac)24.3(id)-255.8(t)16.1(e)0(s)19.9(t)16.1(in)26.5(g)-271.8(i)16.1(s)-265.8(r)0(e)19.7(c)15(om)25.4(me)24.2(nd)26.6(ed)25.4(.)]TJ
7.3823 0 0 6.5614 243.9495 345.8834 Tm
-.0162 Tc
[(6,)-16.2(7)]TJ
9.843 0 0 9.843 72 330.5196 Tm
0 Tc
[(Th)19.6(e)-186.6(r)0(e)19.7(m)0(a)18.4(r)0(k)15.1(a)0(b)19.7(l)0(e)-176.3(e)0(f)19.7()0(c)14.1(a)0(c)18.5(y)-185.4(of)-180.7(th)20.7(e)-186.6(n)0(e)19.7(w)-192(dr)20.9(ug)20.8(s)-185.2(f)0(o)15.1(r)-185.4(he)19.7(pa)19.7(ti)14.8(ti)20.6(s)-185.2(C)-192.2(ha)19.7(s)]TJ
-1.0137 -1.1116 TD
[(in)20.7(ev)19.7(it)14.8(ab)19.7(ly)-163.6(le)19.5(d)-173.9(t)0(o)-169.4(q)0(u)20.8(e)0(s)19.9(t)0(i)20.6(o)0(n)15.1(s)-173.7(ab)19.7(ou)20.8(t)-174(t)0(h)15(e)-175(sa)19.9(fe)19.7(ty)-169.4(of)-163.4(th)20.7(es)19.9(e)-180.8(d)0(r)20.9(u)0(g)20.8(s)-173.7(in)-169.4(th)20.7(e)]TJ
T*
[(nu)20.8(rs)15.3(in)20.7(g)-329.4(m)0(o)13.9(t)0(h)20.7(e)0(r)19.7(.)-331.7(Un)20(fo)15.1(rt)20.7(un)20.8(at)19.5(el)19.5(y,)-327.1(no)20.8(ne)-325.9(of)-319(th)15(es)19.9(e)-336.3(n)0(e)19.7(w)-330.3(dr)15.1(ug)20.8(s)-335(h)0(a)19.7(s)]TJ
T*
[(an)19.7(y)-300.6(h)0(u)20.8(m)0(a)18.4(n)-300.6(in)20.7(fo)20.9(rm)19.6(at)13.8(io)20.7(n)-300.6(r)0(e)19.7(l)0(a)19.6(t)0(i)20.6(v)0(e)-291.3(t)0(o)-290.3(t)0(h)20.7(e)0(i)19.5(r)-300.6(us)21(e)-301.8(i)0(n)-290.3(b)0(r)20.9(e)0(a)18.5(s)0(t)15.1(f)0(e)19.7(e)0(d)19.7(i)0(n)20.7(g)0(.)]TJ
0 -1.1174 TD
[(Th)19.6(e)-261.4(d)0(r)20.9(u)0(g)20.8(s)-260.1(av)19.7(ai)19.5(la)19.6(bl)15(e)-255.7(a)0(t)-251.2(t)0(h)20.7(e)-261.4(ti)20.6(me)-246.5(of)-249.8(wr)20(it)20.6(in)15(g)-254.5(i)0(n)20.7(c)0(l)13.8(u)0(d)20.8(e)-255.7(bo)15.1(ce)18.5(pr)20.9(ev)19.7(ir)20.7(,)]TJ
0 -1.1116 TD
[(da)19.7(cl)19.5(at)13.8(as)19.9(vi)20.7(r,)-373.1(da)19.7(sa)14.1(bu)20.8(vi)20.7(r,)-373.1(el)19.5(ba)13.9(sv)21(ir)20.7(,)-383.6(g)0(r)15.1(a)0(z)18.5(o)0(p)20.8(r)0(e)19.7(v)0(i)20.7(r)0(,)-378.9(l)0(e)19.6(d)0(i)20.7(p)0(a)19.7(s)0(v)21(i)0(r)15(,)-383.6(om)19.6(-)]TJ
T*
[(bi)20.7(ta)19.6(sv)15.3(ir)20.7(,)-268.4(p)0(a)19.7(r)0(i)15(t)0(a)19.5(p)0(r)20.9(e)0(v)19.7(i)0(r)20.7(,)-274.1(pe)19.7(gi)20.7(nt)20.7(er)19.7(fe)14(ro)20.9(ns)-261.2(al)19.5(fa)19.7(-2)20.9(a)-273(a)0(n)19.7(d)-271.8(2b)20.8(,)-268.4(r)0(i)15(b)0(a)19.7(v)0(i)20.7(r)0(i)20.7(n)0(,)]TJ
0 -1.1174 TD
[(si)20.9(me)18.4(pr)15.1(ev)19.7(ir)20.7(,)-372(s)0(o)15.3(f)0(o)20.9(s)0(b)21(u)0(v)20.8(i)0(r)20.7(,)-377.8(an)19.7(d)-375.5(v)0(e)19.7(l)0(p)20.7(a)0(t)19.5(a)0(s)19.9(v)0(i)20.7(r)0(.)-367.4(A)-376.3(lo)20.7(w)-370.6(d)0(o)15.1(s)0(e)-360.3(o)0(f)-365(r)0(i)15(t)0(o)20.7(-)]TJ
0 -1.1116 TD
[(na)19.7(vi)20.7(r)-438.8(i)0(s)-428.3(i)0(n)20.7(c)0(l)13.8(u)0(d)20.8(e)0(d)-429.6(i)0(n)-428.5(s)0(o)21(m)0(e)-425.1(c)0(o)13.9(m)0(b)19.6(i)0(n)20.7(a)0(t)19.5(i)0(o)20.7(n)-438.8(re)19.7(gi)20.7(me)18.4(ns)-428.2(to)-428.5(in)20.7(hi)15(bi)20.7(t)]TJ
T*
[(CY)18.9(P3)21(A4)-354.4(me)18.4(ta)19.5(bo)20.8(li)20.6(sm)-354.6(of)-347.7(a)-359.4(c)0(o)13.9(n)0(c)19.7(o)0(m)19.6(i)0(t)20.6(a)0(n)19.7(t)-358.3(pr)15.1(ot)20.7(ea)18.5(se)-348.7(in)14.9(hi)20.7(bi)20.7(to)20.7(r)-363.9(t)0(o)]TJ
0 -1.1174 TD
[(en)19.7(ha)19.7(nc)19.7(e)-273(i)0(t)20.6(s)-271.6(or)20.9(al)-262.7(bi)20.7(oa)19.7(va)13.9(il)20.6(ab)19.7(il)20.6(it)20.6(y.)]TJ
1.0137 -1.1116 TD
[(The)-391.6(FDA-approved)-397.2(labeling)-391.7(of)-393.8(hepatitis)-392.7(C)-393.8(drugs)-391.2(is)-393.8(dis-)]TJ
-1.0137 -1.1116 TD
[(tinctly)-291.6(divided)-297.1(between)-294.4(drugs)-293.3(approved)-293.3(before)-291.1(and)-292.5(after)-295.9(the)]TJ
0 -1.1174 TD
[(new)-368.2(FDA)-367.7(Pregnancy)-376.1(and)-367.3(Lactation)-372.1(Labeling)-369.7(Rule)-369.6(\(PLLR\))]TJ
0 -1.1116 TD
[(took)-304(effect)-303.9(on)-301.7(June)-299.1(30,)-299.4(2015.)-301.6(Drugs)-305.7(approved)-299.1(before)-308.4(PLLR)]TJ
T*
[(include)-338.6(boceprevir,)-340.6(alfa)-340.9(interferons,)-340.4(ribavirin,)-337.4(and)-338.5(simepre-)]TJ
T*
[(vir.)-329.4(The)-328.2(labels)-331.5(of)-324.7(these)-330.3(drugs)-327.8(contain)-332.8(the)-327.1(familiar)-329.5(wording,)]TJ
0 -1.1174 TD
[()50.8(It)-291.4(is)-284.4(not)-285.7(known)-288.6(whether)-293.2(drug)-286.6(x)-283.3(i)0(s)-290.1(excreted)-290(in)-284.5(human)-290.1(milk.)]TJ
0 -1.1116 TD
[(Because)-347.3(of)-342(the)-338.7(potential)-346.8(for)-343.1(serious)-342.6(adverse)-345(reactions)-341.7(from)]TJ
T*
[(the)-292.6(drug)-286.6(in)-290.3(nursing)-289.8(infants,)-288.8(a)-290.2(decision)-287.7(should)-294.5(be)-285.6(made)-290.2(whe-)]TJ
0 -1.1174 TD
[(ther)-190(to)-186.6(discontinue)-193.2(nursing)-186.2(or)-186.5(to)-186.6(delay)-192.3(or)-186.5(discontinue)-193.2(drug)-182.9(x.)46.2()]TJ
0 -1.1116 TD
[(Drugs)-420.9(approved)]TJ
/F10 1 Tf
7.0038 0 TD
(after)Tj
/F7 1 Tf
2.3154 0 TD
[(the)-419.3(PLLR)-422.4(have)-421.4(the)-419.3(much)-421.5(improved)]TJ
-9.3192 -1.1116 TD
[(wording)-285.1(of,)-282.1()50.8(the)-282.1(development)-287.8(and)-280.9(health)-285.7(benets)-286.3(of)-284.4(breast-)]TJ
0 -1.1174 TD
[(feeding)-194.4(should)-196.6(be)-193.4(considered)-198.7(along)-196.9(with)-195.6(the)-194.7(mothers)-195.4(clinical)]TJ
0 -1.1116 TD
[(need)-456(for)-446.7(drug)-453.6(x)-450.4(and)-453.7(any)-448(potential)-456.3(adverse)-454.5(effects)-454.6(on)-451.5(the)]TJ
T*
[(breastfed)-278.2(child)-271.9(from)-270.5(drug)-275.1(x)-271.8(o)0(r)-272.9(from)-270.5(the)-275.3(underlying)-271.6(maternal)]TJ
25.504 67.9242 TD
[(condition.)47.4()-185.4(These)-187.4(differences)-189.4(in)-180.9(wording)-187.2(appear)-182.9(to)-186.6(be)-181.9(merely)]TJ
0 -1.1174 TD
[(artifacts)-243.9(of)-238.3(the)-240.7(PLLR)-238.1(labeling)-241.9(changes)-241.4(and)-234.8(not)-239.6(related)-241.8(to)-238.5(any)]TJ
0 -1.1116 TD
[(inherent)-189.9(difference)-188.5(in)-180.9(risk)-182.8(between)-185(the)-188.9(older)-179.6(and)-188.8(newer)-181.5(drugs.)]TJ
1.0137 -1.1116 TD
[(La)18.5(b)16.2(e)0(l)19.6(i)0(n)26.5(g)-300.6(th)20.7(at)-291.5(a)15(l)0(l)-290.4(h)0(e)19.7(p)16.2(at)19.5(it)26.3(is)-290.1(C)-301.6(d)0(r)20.9(u)0(g)26.6(s)-306.2(h)16.2(a)0(v)19.7(e)-301.8(in)-290.3(c)15(o)0(m)19.6(m)15(on)-290.2(is)20.9(,)-302.9()62.3()16.2(i)0(f)]TJ
-1.0137 -1.1116 TD
[(dr)20.9(ug)-405.4(x)-415.8(i)16.1(s)-415.6(a)0(d)19.7(m)15(in)20.7(is)20.9(t)16(e)0(r)19.7(e)0(d)-400.8(w)0(i)19.8(t)0(h)-405.5(r)16.2(ib)20.7(av)25.4(ir)20.7(in)26.5(,)-418.1(t)0(h)26.5(e)-417(nu)20.8(rs)26.8(in)20.7(g)-415.8(m)15(ot)20.7(he)25.4(r)20.9(s)]TJ
0 -1.1174 TD
[(in)20.7(fo)20.9(r)16.2(m)0(a)18.4(t)16.1(io)20.7(n)-266(f)0(o)20.9(r)-271.8(r)16.2(i)0(b)20.7(a)0(v)25.4(i)0(r)20.7(i)0(n)-255.7(a)0(l)19.5(s)16.4(o)-271.8(a)0(p)25.4(p)0(l)20.7(i)0(e)25.3(s)-271.6(to)-255.8(th)20.7(i)16.1(s)-271.6(co)19.7(m)15(b)0(i)20.7(n)16.2(at)19.5(io)26.5(n)-271.8(r)0(e)25.5(g)0(-)]TJ
0 -1.1116 TD
[(im)19.5(en)25.4(.)-297.2(R)0(e)18.6(f)16.2(er)-291.3(t)16(o)-300.6(th)26.5(e)-301.8(r)0(i)26.5(b)0(a)19.7(v)16.2(ir)20.7(in)-284.6(pr)20.9(e)15(s)0(c)19.9(r)0(i)20.7(b)16.2(in)20.7(g)-294.8(i)0(n)20.7(f)0(o)26.6(r)0(m)19.7(a)15(ti)20.6(on)-284.4(fo)20.9(r)-294.8(m)0(o)25.4(r)0(e)]TJ
T*
[(in)20.7(fo)20.9(r)16.2(m)0(a)18.4(t)16.1(io)20.7(n)-260.3(o)0(n)-255.6(u)0(s)26.8(e)-267.2(du)26.6(ri)20.7(ng)-249.9(la)19.6(c)15(t)0(a)19.5(t)0(i)26.3(o)0(n)20.8(.)13.9()62.3()-266(Of)-250.7(co)19.7(u)16.2(r)0(s)21.1(e)0(,)-253.4(r)0(i)20.7(b)16.2(av)19.7(i)16(r)0(i)20.7(n)-266(h)16.2(a)0(s)]TJ
0 -1.1174 TD
[(th)20.7(e)-330.6(o)0(l)20.7(d)-329.4(la)19.6(b)16.2(e)0(l)19.5(i)16.1(ng)-324.7(a)15(n)0(d)-319(a)0(d)19.7(m)15(on)20.8(it)26.3(io)20.7(n)-329.4(t)0(o)-319.1(s)0(t)20.9(o)0(p)-319(b)0(r)26.6(e)0(a)18.5(s)0(t)26.7(f)0(e)19.7(e)0(d)25.4(i)0(n)20.7(g)-329.4(if)-319.1(it)-319.2(is)]TJ
0 -1.1116 TD
[(us)21(ed)19.7(.)-285.7(R)15.2(ib)20.7(av)25.4(ir)20.7(in)-273(is)-278.6(te)25.3(ra)19.7(t)16.1(o)0(g)20.8(e)0(n)25.4(i)0(c)-280(a)15(nd)-278.7(em)24.2(br)20.9(y)16.2(o)0(c)19.7(i)0(d)26.5(a)0(l)-280(i)16.1(n)-289.1(a)0(n)25.4(i)0(m)19.5(a)0(l)25.3(s)0(,)-275(s)0(o)]TJ
T*
-.0193 Tc
[(i)-19.3(t)1.3(s)-360(u)-19.3(se)-361.4(du)-19.3(ri)-19.3(ng)-360.2(pr)-19.3(eg)-19.3(n)7.3(a)-19.3(ncy)-366(i)-3.2(s)-360(c)-19.3(on)-19.3(t)7.2(r)-19.3(ai)-19.3(n)7.2(d)-19.3(ic)-19.3(at)-19.3(ed,)-362.5(a)-19.3(lth)-19.3(o)1.5(u)-19.3(g)7.3(h)-360.2(h)-19.3(uma)-19.3(n)]TJ
0 -1.1174 TD
0 Tc
[(pr)20.9(eg)25.4(na)19.7(nc)25.4(y)-225.7(d)16.2(at)19.5(a)-221.1(a)0(r)25.5(e)-221.1(li)20.6(mi)25.2(te)19.5(d)-220(a)0(n)25.4(d)-225.7(i)16.1(n)0(c)19.7(o)0(n)26.6(c)0(l)19.5(u)16.2(si)20.9(ve)19.7(.)-216.5(T)0(h)19.6(e)15(se)-210.5(pr)20.9(eg)25.4(na)19.7(n)16.2(c)0(y)]TJ
0 -1.1116 TD
[(co)19.7(nc)25.4(er)19.7(ns)-353.4(ar)19.7(e)-370.9(n)16.2(ot)-359.4(re)25.5(le)19.5(va)25.4(nt)-359.4(t)16.1(o)-369.7(nu)20.8(r)16.2(s)0(i)20.9(n)0(g)-359.3(i)16.1(nf)20.9(an)25.4(ts)20.9(,)-366.3(a)0(n)19.7(d)-364(in)20.7(fa)25.5(nt)20.7(s)-369.5(a)15(re)]TJ
T*
[(of)20.9(te)25.3(n)-323.6(t)16.1(re)19.7(at)25.3(ed)-308.6(di)20.7(r)16.2(e)0(c)18.5(t)0(l)26.3(y)-317.9(wi)19.8(th)-307.6(ri)26.5(ba)19.7(vi)26.5(ri)20.7(n)-317.9(i)0(n)20.7(h)16.2(al)19.6(a)15(t)0(i)20.6(o)0(n)-307.5(f)0(o)26.6(r)-317.8(re)19.7(sp)21(i)16.1(r)0(a)19.7(t)0(o)26.5(r)0(y)]TJ
T*
[(sy)21(nc)19.7(y)16.2(t)0(i)20.6(a)15(l)-271.9(v)0(i)26.5(r)0(u)20.9(s)-265.8(wi)19.8(th)-255.8(fe)25.5(w)-272.7(n)0(o)26.6(n)0(p)20.8(u)0(l)26.5(m)0(o)19.6(n)16.2(ar)19.7(y)-266(s)0(i)20.9(d)0(e)-256.8(e)0(f)25.5(f)0(e)19.7(c)0(t)25.3(s)0(.)]TJ
/F9 1 Tf
8.9663 0 0 8.9663 313.0582 550.1479 Tm
[(The)-337(evidence)]TJ
/F7 1 Tf
9.843 0 0 9.843 323.0361 533.7069 Tm
[(Authors)-475(from)-477.9(Italy)-473.4(have)-473.3(recen)-9(tly)-470.1(addressed)-479.5(the)-476.9(use)-470.8(of)]TJ
-1.0137 -1.1174 TD
[(hepat)-8(itis)-557.5(C)-560.8(drugs)-558.2(during)-559.6(pregnancy)-560.5(and)-557.4(breastfeeding.)]TJ
7.3823 0 0 6.5614 544.8187 527.0739 Tm
(10)Tj
9.843 0 0 9.843 313.0582 511.7668 Tm
[(Because)-468.2(of)-457.2(the)-459.6(lack)-461.9(of)-462.9(human)-457.2(data,)-465.3(they)-460.7(approached)-464.9(the)]TJ
0 -1.1116 TD
[(topics)-353.4(from)-356.9(the)-350.2(standpoints)-353.1(of)-353.5(the)-350.2(drugs)-351.9(pharmacokinetics)]TJ
0 -1.1174 TD
[(and)-263.7(animal)-263.9(studies.)-259.8(Unfortunately,)-269(the)-258(article)-265(often)-260.2(conates)]TJ
0 -1.1116 TD
[(pregnancy)-209.2(and)-200.3(lactation)-204(risks)-206.8(\(which)-198.8(is)-203.7(not)-199.3(generally)-209.5(true\),)-200.2(so)]TJ
T*
[(its)-694.5(recommendation)-11.3(s)-692.1(are)-696.8(occasionally)-697.7(puzzling.)-694.5(Never-)]TJ
T*
[(theless,)-301.3(the)-292.6(authors)-291(point)-293.8(out)-297.2(that)-293.8(the)-292.6(drugs)-293.3(have)-294.7(not)-291.4(caused)]TJ
0 -1.1174 TD
[(any)-286.7(adverse)-287.4(effects)-281.8(in)-284.5(the)-281.1(pups)-286.4(of)-278.6(lactating)-290.4(animals)-282(and)-286.7(that)]TJ
0 -1.1116 TD
[(the)-327.1(pharmacokinetic)-329.2(properties)-330.1(of)-324.7(these)-324.6(drugs)-327.8(are)-328.1(generally)]TJ
T*
(favorable.)Tj
1.0137 -1.1174 TD
[(Plasma)-269.1(protein)-274(binding)-267.2(of)-267.1(most)-270.5(of)-267.1(the)-269.5(hepatitis)-266(C)-272.8(drugs)-264.5(is)]TJ
-1.0137 -1.1116 TD
[(quite)-289.2(extensive.)-287.6(With)-283.4(the)-286.8(exception)-284.4(of)-284.4(boceprevir)-291(\(75%\),)-280.7(ri-)]TJ
T*
[(bavirin)-268.3(\(0%\),)-262.3(and)-263.6(sofosbuvir)-264.1(\(60%)-264.6(drug,)-267(0%)-262.5(metabolite\),)-268.4(all)]TJ
0 -1.1174 TD
[(of)-393.8(the)-390.5(other)-392.7(oral)-391.6(drugs)-391.2(for)-389.1(hepatitis)-392.7(C)-393.8(are)-391.5(more)-392.7(than)-391.6(97%)]TJ
0 -1.1116 TD
[(bound)-305(to)-296.1(maternal)-307.5(proteins)-298(and)-304(most)-299.3(of)-301.7(them)-300.7(are)-305.1(more)-300.5(than)]TJ
T*
[(99%)-223.2(bound.)-216.3(This)-218.6(means)-222(that)-218.9(less)-218.4(than)-218.8(13%)-218.6(of)-215.3(these)-220.9(drugs)-218.4(in)]TJ
0 -1.1174 TD
[(maternal)-261.4(plasma)-257.8(will)-259.1(pass)-258.6(into)-258.1(breastmilk.)-254.3(Extensive)-261.2(protein)]TJ
0 -1.1116 TD
[(binding)-353.6(is)-353.5(a)-353.6(relatively)-354.8(good)-350(predictor)-358(of)-353.5(low)-349.9(infant)-353.6(plasma)]TJ
T*
[(levels)-285.5(and)-280.9(safe)-283(drug)-280.8(use)-280.7(during)-283.2(breastfeeding.)]TJ
7.3823 0 0 6.5614 495.4392 329.8393 Tm
(11)Tj
9.843 0 0 9.843 323.0361 314.5322 Tm
[(Given)-652.8(the)-643.9(favorable)-652.8(pharmacokinetics,)-656.1(generally)-653(low)]TJ
-1.0137 -1.1174 TD
[(toxicity,)-434.4(and)-430.7(the)-430.8(relatively)-435.4(permissive)-434.9(product)-429.4(labeling)-432(of)]TJ
0 -1.1116 TD
[(most)-351.2(drugs)-345.1(for)-343.1(hepatitis)-346.6(C,)-345.4(LactMed)-353.3(uses)-345(the)-344.4(standard)-350.9(lan-)]TJ
T*
[(guage)-382.2(of,)-380()50.8(If)-377.6(drug)-378.8(x)-375.5(i)0(s)-376.5(required)-379.8(by)-376.6(the)-379(mother,)-381.2(it)-376.8(is)-376.5(not)-377.8(a)]TJ
0 -1.1174 TD
[(reason)-417.6(to)-417(discontinue)-417.8(breastfeeding.)-419.8(Some)-415.6(sources)-418.6(recom-)]TJ
0 -1.1116 TD
[(mend)-352.4(against)-349.9(breastfeeding)-353(when)-352(drug)-350(x)-346.7(i)0(s)-347.7(used)-351(with)-351.1(riba-)]TJ
T*
[(virin.)47.4()-433(The)-437.6(information)-435.3(on)-434.2(the)-430.8(lack)-438.8(of)-434.1(transmissibility)-435(of)]TJ
0 -1.1174 TD
[(hepat)-8(itis)-379(C)-388(through)-382.2(breastmilk)-383.4(except)-390.4(for)-383.4(the)-379(possible)-390(risk)]TJ
0 -1.1116 TD
[(with)-385.7(cracked)-386.7(nipples)-383.3(and)-378.8(information)-389.2(on)-376.6(infant)-388.1(testing)-383.4(are)]TJ
T*
[(also)-282(included)-287.9(in)-278.8(each)-284.4(LactMed)-284.1(record.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 313.0582 194.3432 Tm
[(Disclosure)-336.7(Statement)]TJ
/F7 1 Tf
9.843 0 0 9.843 323.0361 177.9023 Tm
[(No)-279.5(competing)-284.4(nancial)-283.1(interests)-288.7(exist.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 313.0582 156.3023 Tm
(References)Tj
/F7 1 Tf
9.2951 0 0 9.2951 317.707 140.2582 Tm
[(1.)-500.4(Dionne-Odom)-333.5(J,)-328.7(Tita)-334.9(AT,)-327.1(Silverman)-330.5(NS.)-334.2(#38:)-323.3(Hepatitis)-337.5(B)]TJ
1.2503 -1.1284 TD
[(in)-384(pregnancy)-388.3(screening,)-386.9(treatment,)-386.2(and)-382.8(prevention)-389.2(of)-380.8(ver-)]TJ
0 -1.1223 TD
[(tical)-336.8(transmission.)]TJ
/F10 1 Tf
7.7216 0 TD
[(Am)-333.1(J)-333.7(Obstet)-334(Gynecol)]TJ
/F7 1 Tf
9.0696 0 TD
(2016;214:614.)Tj
-18.0415 -1.1284 TD
[(2.)-500.4(Ehrhardt)-261.4(S,)-259.3(Xie)-261.8(C,)-261.2(Guo)-258.2(N,)-258(et)-260.1(al.)-260.2(Breastfeeding)-270.1(while)-255.4(taking)]TJ
1.2503 -1.1223 TD
[(lamivudine)-398.1(or)-393(tenofovir)-393.3(disoproxil)-391.5(fumarate:)-395.1(A)-398.2(review)-390.8(of)]TJ
0 -1.1284 TD
[(the)-339.5(evidence.)]TJ
/F10 1 Tf
5.7211 0 TD
[(Clin)-333.6(Infect)-333.7(Dis)]TJ
/F7 1 Tf
6.4042 0 TD
(2015;60:275278.)Tj
-13.3756 -1.1223 TD
[(3.)-500.4(Rosenthal)-567.5(P.)-564.2(Editorial)-568.6(commentary:)-563.5(The)-567.7(conundrum)-562.4(of)]TJ
1.2503 -1.1284 TD
[(lamivudine)-361.5(and)-352.3(tenofovir)-356.7(disoproxil)-354.9(fumarate)-352.9(for)-358.8(hepatitis)]TJ
0 -1.1223 TD
[(B:)-333.9(Fetus)-335.7(versus)-335(infant.)]TJ
/F10 1 Tf
9.5941 0 TD
[(Clin)-333.6(Infect)-339.8(Dis)]TJ
/F7 1 Tf
6.4103 0 TD
(2015;60:279280.)Tj
/F8 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(2)Tj
44.7536 0 TD
(LACTMED)Tj
/F2 1 Tf
6.7246 0 0 5.9768 507.0613 753.6754 Tm
()Tj
/F8 1 Tf
8.9663 0 0 8.9663 515.3951 749.6502 Tm
(UPDATE)Tj
ET
endstream
endobj
31 0 obj
<>stream
/GS1 gs
BT
/F7 1 Tf
9.2951 0 0 9.2951 64.4031 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(4.)-500.4(Visvanathan)-526.1(K,)-526.3(Dusheiko)-523.9(G,)-520.2(Giles)-522.9(M,)-524(et)-522.4(al.)-522.4(Managing)]TJ
1.2503 -1.1223 TD
[(HBV)-313.3(in)-304.7(pregnancy.)-309.1(Prevention,)-306.8(prophylaxis,)-311.1(treatment)-313(and)]TJ
0 -1.1284 TD
[(follow-up:)-317(Position)-312.5(paper)-316.4(produced)-316.9(by)-311.3(Australian,)-316.2(UK)-320.6(and)]TJ
0 -1.1223 TD
[(New)-337.1(Zealand)-338.2(key)-334(opinion)-335.3(leaders.)]TJ
/F10 1 Tf
14.3942 0 TD
(Gut)Tj
/F7 1 Tf
1.8359 0 TD
(2016;65:340350.)Tj
-17.4804 -1.1283 TD
[(5.)-500.4(Anonymous.)-355.4(LactMed.)-355.8(National)-357.1(Library)-358.8(of)-350.3(Medicine.)-359.6(Na-)]TJ
1.2503 -1.1223 TD
[(tional)-442.5(Institutes)-443.1(of)-435.7(Health.)-442.8(Available)-440.7(at)-443.1(http://toxnet.nlm.)]TJ
0 -1.1284 TD
[(nih.gov/cgi-bin/sis/htmlgen?LACTMED)-245(\(accessed)-242.5(June)-235.7(13,)]TJ
0 -1.1223 TD
(2016\).)Tj
-1.2503 -1.1284 TD
[(6.)-500.4(Cottrell)-400.5(EB,)-391.3(Chou)-395.7(R,)-395.3(Wasson)-391.9(N,)-392.1(et)-400.4(al.)-394.3(Reducing)-391.9(risk)-397.9(for)]TJ
1.2503 -1.1223 TD
[(mother-to-infant)-401.5(transmission)-399.9(of)-393(hepatitis)-396.9(C)-395.3(virus:)-397.6(A)-398.2(sys-)]TJ
0 -1.1284 TD
[(tematic)-249.3(review)-244.4(for)-242.9(the)-248(U.S.)-242.8(Preventive)-243.8(Services)-249.3(Task)-243.7(Force.)]TJ
/F10 1 Tf
0 -1.1223 TD
[(Ann)-337.8(Intern)-335.3(Med)]TJ
/F7 1 Tf
6.8433 0 TD
(2013;158:109113.)Tj
-8.0937 -1.1284 TD
[(7.)-500.4(Workowski)-374.1(KA,)-375.6(Bolan)-369(GA.)-375.6(Sexually)-371.2(transmitted)-374.7(diseases)]TJ
1.2503 -1.1284 TD
[(treatment)-313(guidelines,)-318.4(2015.)]TJ
/F10 1 Tf
11.3568 0 TD
[(MMWR)-314.8(Recomm)-313.2(Rep)]TJ
/F7 1 Tf
9.0574 0 TD
(2015;64:)Tj
-20.4141 -1.1223 TD
(1137.)Tj
-1.2503 -1.1284 TD
[(8.)-500.4(Pfaender)-411.7(S,)-405.7(Heyden)-407.3(J,)-408(Friesland)-409.3(M,)-402(et)-406.5(al.)-406.5(Inactivation)-410.8(of)]TJ
1.2503 -1.1223 TD
[(hepatitis)-317.6(C)-309.9(virus)-312.6(infectivity)-320.5(by)-311.3(human)-309.5(breast)-315.1(milk.)]TJ
/F10 1 Tf
20.9265 0 TD
[(J)-309.3(Infect)]TJ
-20.9265 -1.1284 TD
(Dis)Tj
/F7 1 Tf
1.72 0 TD
(2013;208:19431952.)Tj
24.0432 19.1333 TD
-.0189 Tc
[(9)-18.9(.)-519.3(Tovo)-476.5(PA,)-470.3(C).6(alitri)-475.9(C).6(,)-470.3(S)-3.6(colfaro)-476.5(C)]TJ
14.3271 0 TD
-.0181 Tc
[(,)-475.6(e)2(t)-475.1(a)2(l.)-469.5(Vertically)-469.6(acqu)6.2(ired)]TJ
-13.0768 -1.1223 TD
-.0185 Tc
[(hepatitis)-267.8(C)-261.3(v)-.3(irus)-261.7(infection:)-262(C)-5.1(o)5.8(rrelates)-267.8(o)-.3(f)-264.9(t).2(ransmission)-262.6(and)-268.7(d)-.3(is-)]TJ
0 -1.1284 TD
-.0189 Tc
[(ease)-261.1(p)-.7(rogression.)]TJ
/F10 1 Tf
6.8616 0 TD
[(World)-263(J)-261.1(Gastroenterol)]TJ
/F7 1 Tf
8.9781 0 TD
-.0183 Tc
[(2016;2)6(2)-.1(:13821)6(392.)]TJ
-17.5902 -1.1223 TD
0 Tc
[(10.)-500.5(Spera)-264.4(AM,)-269.6(Eldin)-263.7(TK,)-266.1(Tosone)-268.3(G,)-264.1(et)-266.2(al.)-266.3(Antiviral)-269.4(therapy)-267.3(for)]TJ
1.7505 -1.1283 TD
[(hepatitis)-464(C:)-468(Has)-462.8(anything)-467.8(changed)-465(for)-468.6(pregnant/lactating)]TJ
0 -1.1223 TD
(women?)Tj
/F10 1 Tf
3.7266 0 TD
[(World)-337.2(J)-333.7(Hepatol)]TJ
/F7 1 Tf
7.1788 0 TD
(2016;8:557565.)Tj
-12.6559 -1.1284 TD
[(11.)-500.5(An)22.5(de)19.9(rs)16.6(on)-256.5(GD)14.9(.)-268.4(U)0(s)17.3(i)12.6(ng)-256.5(ph)18(ar)17.6(m)12.5(a)0(c)15.7(o)0(k)18(i)12.6(ne)19.9(ti)19.2(cs)-259.8(to)-262(pr)21.8(ed)19.9(ic)14.4(t)-267.9(t)12.6(he)-260.7(ef)17.6(fe)17.6(ct)20.5(s)]TJ
1.7505 -1.1223 TD
[(of)-417.4(pr)21.8(eg)13.8(na)19.9(nc)19.9(y)-427.1(a)0(n)19.9(d)-433.2(m)12.5(a)0(t)14.4(e)14(rn)15.7(al)20.5(-i)16.3(nf)21.8(an)19.9(t)-432.6(t)12.6(ra)17.6(ns)18.9(fe)17.6(r)-429.4(o)0(f)-417.4(d)0(r)21.8(u)0(g)18(s)-432.3(du)24.1(ri)16.3(ng)]TJ
0 -1.1284 TD
-.0131 Tc
[(la)-13.1(cta)-13.1(t)1.3(io)-13.1(n)4.9(.)]TJ
/F10 1 Tf
3.8791 0 TD
0 Tc
[(Ex)18(pe)19.9(rt)-248.9(Op)22.5(in)-249.8(Dr)23.4(ug)-244.3(Me)17.4(ta)18.6(b)-256.3(T)0(o)21.2(x)0(i)20.5(c)0(o)19.9(l)]TJ
/F7 1 Tf
13.4183 0 TD
[(20)18(06)18(;)12.6(2)0(:)18.6(9)0(4)18(7)0()24.1(9)0(6)18(0)0(.)]TJ
9.843 0 0 9.843 438.803 623.0549 Tm
[(Address)-331.9(correspondence)-343.5(to:)]TJ
/F10 1 Tf
-.6566 -1.1116 TD
[(Philip)-330.7(O.)-333.7(Anderson,)-336.8(PharmD)]TJ
-11.8765 -1.1174 TD
[(Skaggs)-330.1(School)-336.2(of)-336.4(Pharmacy)-335.6(and)-331.6(Pharmaceutical)-343.7(Sciences)]TJ
9.1579 -1.1116 TD
[(University)-337.9(of)-330.6(California,)-338.4(San)-331.6(Diego)]TJ
6.7158 -1.1116 TD
[(9500)-332.7(Gilman)-336.9(Drive)]TJ
-2.4767 -1.1174 TD
[(La)-330.3(Jolla,)-338.7(CA)-332.7(92093-0657)]TJ
-2.0332 -2.1253 TD
(E-mail:)Tj
/F7 1 Tf
3.3982 0 TD
(phanderson@ucsd.edu)Tj
/F8 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
(LACTMED)Tj
/F2 1 Tf
6.7246 0 0 5.9768 103.5779 753.6754 Tm
()Tj
/F8 1 Tf
8.9663 0 0 8.9663 111.9118 749.7069 Tm
(UPDATE)Tj
48.3007 0 TD
(3)Tj
ET
endstream
endobj
35 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
36 0 obj
<>stream
htWyTSw轉U"ܫֵ֭KZEdEKX@XeZ[-u~iV6~osfn93swrn}y^?T_nݱtKrAQ.y8T$<;sf
(oƉ4pigp*[ee+4 vqRk^]z
]CV
$g
(eraL+3)K%M[bAC&ʄ\.P&41Y(=&J2l`YR,L,JUǏqfsp ~8S88+8ps8[yPs`*'ʏ2K
g*,r,))G|4=S`+<<ojxsyNL;8⩙OE?̘=p3f~Op$,bVìI4,q䰴SO4&%d|/> P
M}]Wa
$e`h1"l
f"
Fң
`C4HUwQ(܁A8,:>yyR4ۄVFMvG3{#Z $T 1{A
D/2j/RD,P)EܸoÞ0- I5SX=ᶡ-Ji>OPaȅ?21
xҟr2h:Bz9-:}"@~b+=Ȏh«¦sPk,&
1kZ2|x^o!&
ń@
Sܕ의OWb
hNmM'L~}\ciB 7ޙ 4Ew~626H- hBo : ފ8d:!JL-2e薴f1OVqT"*︉⪂yoIp46;!
ELyX6
)v$A( ,#'U-uQh0F]̲'&.ڌ"Ri0ڣ12up,=XTa>nJ^0,nʜ=W